Dynamics of the Anti-factor VIII Antibody Signature During Treatment With Emicizumab

RecruitingOBSERVATIONAL

Enrollment

100

Participants

Timeline

Start Date

April 26, 2023

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2029

Conditions

Severe Hemophilia ASevere Hemophilia A With InhibitorSevere Hemophilia A Without Inhibitor

Interventions

OTHER

no interventions

no intervention, only 3 different patients groups

Trial Locations (1)

RECRUITING

University Hospital Frankfurt, Goethe University, Frankfurt am Main

All Listed Sponsors

collaborator

Roche Pharma AG

INDUSTRY

collaborator

Chugai Pharma Germany GmbH

UNKNOWN

lead

Christoph Königs

OTHER

NCT05802836 - Dynamics of the Anti-factor VIII Antibody Signature During Treatment With Emicizumab | Biotech Hunter | Biotech Hunter